Texas gives green-light for experimental stem-cell therapies – LifeNews.com

The government of Texas will allow clinics across the state to market unapproved stem-cell therapies, in a move that has met with criticism from bioethicists.

Last week Governor Greg Abbott signed off on the new legislation that allows clinics to by-pass FDA approval for investigational stem cell treatments for patients with certain severe chronic diseases or terminal illnesses. Like right to try laws in other States, the Texas legislation will give desperate patients access to therapies that provide hope after traditional medical treatments have failed.

Currently, most patients wishing to have stem-cell therapy have to travel out of the country to receive it. The new law will allow people with severe chronic or terminal illness to be treated at a clinic that purports to isolate therapeutic stem cells from adult tissuesuch as a patients own fatif their doctor recommends it after considering all other options, and if its administered by a physician at a hospital or medical school with oversight from an institutional review board (IRB). It also requires that the same intervention already be tested on humans in a clinical trial.

Click here to sign up for pro-life news alerts from LifeNews.com

The law sanctions a much broader set of therapies than federal rules, which already exempt certain stem cell interventions from FDAs lengthy approval process, provided the cells are only minimally manipulated and perform the same function they normally have in the body.

Bioethicists have expressed their concern at the move, which they say puts patients at risk of the effects of dangerous, untested therapies.

University of Minnesota bioethicist Leigh Turner said he was sceptical about whether the clinics would be adequately monitored, while NYU Langone Medical Center bioethicist Beth Roxland said it was insufficient to have the therapies tested in clinical trials while by-passing FDA approval. You could gain access to something [as long as its] being studied in a human somewhere on the planet, Roxland told Science, which in the stem cell area makes it really very scary.

LifeNews Note: This appeared at Bioedge.org and is reprinted with permission.

The rest is here:
Texas gives green-light for experimental stem-cell therapies - LifeNews.com

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell … – PR Newswire (press release)

(Logo: http://mma.prnewswire.com/media/527086/Neovii_Pharmaceuticals_Logo.jpg )

"The significantly improved composite endpoint 'Severe GvHD free and relapse free survival' clearly indicates the impact of ATLG in the cure of patients without ongoing morbidity, which is the main aim of allogeneic stem cell transplantation. This is supported by the fact that the vast majority of patients alive after ATLG-containing GvHD prophylaxis are free of immunosuppressive therapy," said Professor Jrgen Finke, the principal investigator of the study and Deputy Head of the Department of Hematology and Oncology at the Faculty of Medicine and Medical Center at the University of Freiburg, Germany. Professor Finke is also Chairman of the German Stem Cell Transplant Working Group (DAG-KBT). He added, "The results clearly demonstrate the importance of ATLG administration in matched unrelated stem cell transplantation and will certainly influence decision-making and patient counselling in the long run."

Alexandre Sudarskis, CEO of Neovii, commented, "These ground-breaking results undoubtedly prove the long-term efficacy of Grafalon administration as part of a myeloablative conditioning regimen." He added, "Neovii strives to better meet the needs of our patients and to improve their quality-of-life with our effective antibody therapies, allowing physicians to apply a safe and robust therapy." Neovii supports research and development activities in the fields of stem cell transplantation, solid organ transplantation, and immune and hemato-oncological disorders.

About the study

Prospective, multicenter, open-label, randomized, phase 3 study of Grafalon comparing standard ciclosporin A and methotrexate containing GvHD prophylaxis. Patients were randomized to either receive or not receive Grafalon. The study was conducted in 9 European countries and Israel in 31 study centers, enrolling 202 patients. Patients had acute leukemia or myelodysplastic syndrome or myeloproliferative disease in an early (n=107) or advanced disease status (n=94). After myeloablative conditioning, patients received transplantation of blood stem cells (n=164) or bone marrow grafts (n=37). Study results were published in 2009[2] and 2011[3].

About GvHD

Graft versus host disease (GvHD) is a serious, life threatening complication after allogeneic stem cell transplantation. It develops when the new immune system, which arises from the transplanted stem cells (graft), attacks tissues and organs of the recipient (host). It can be classified as acute or chronic, depending on the time of occurrence and/or the pathology.

About Grafalon

Grafalon (formerly commercialized as ATG Fresenius), is a rabbit anti-human T-lymphocyte immunoglobulin, used as part of immunosuppressive regimens for the prevention of graft versus host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation or as immunosuppressive in the treatment of aplastic anemia (according to country-specific approved indications). With more than 200,000 treated patients to date in more than 50 countries, Grafalon enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of their patients around the world.

About Neovii

Neovii is an independent, dynamic and rapidly-growing global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies. Neovii has been dedicated for over three decades to improving outcomes in transplantation medicine, hemato-oncological and immune disorders.

Neovii Pharmaceuticals AG global headquarters is in Rapperswil, Switzerland, with offices in Massachusetts, USA. Its biologics manufacturing facility is in Grfelfing, Germany.

Neovii has a global reach with products sold in over 50 countries worldwide.

References

[1] Finke, Jrgen et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. The Lancet Haematology, June 2017; 4(6):e293-e301.

[2] Finke, Jrgen et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology, September 2009; 10(9):855-64.

[3] Soci, Gerard et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood, June 2011; 117(23):6375-82.

For further information

Contact info@neovii.com or call us at +41 55 210 05 00. For details on the full publication, visit http://www.thelancet.com.

SOURCE Neovii Pharmaceuticals AG

Here is the original post:
Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell ... - PR Newswire (press release)

Study shines light on brain cells that coordinate movement – Medical Xpress

June 26, 2017 In this image of neurons in the cerebellum of the brain, the yellow cells are Purkinje cells in which the channelrhodopsin-2 gene is being produced. Credit: Horwitz Lab/UW Medicine Seattle

UW Medicine researchers have developed a technique for inserting a gene into specific cell types in the adult brain in an animal model.

Recent work shows that the approach can be used to alter the function of brain circuits and change behavior. The study appears in the journal Neuron in the NeuroResources section.

Gregory Horwitz, associate professor of physiology and biophysics at the University of Washington School of Medicine in Seattle, led the research team. He said that the approach will allow scientists to better understand what roles select cell types play in the brain's complex circuitry.

Researchers hope that the approach might someday lead to developing treatments for conditions, such as epilepsy, that might be curable by activating a small group of cells.

"The brain is made up of a mix of many cell types performing different functions. One of the big challenges for neuroscience is finding ways to study the function of specific cell types selectively without affecting the function of other cell types nearby," Horwitz said. "Our study shows it is possible to selectively target a specific cell type in an adult brain using this technique and affect behavior nearly instantly."

In their study, Horowitz and his colleagues at the Washington National Primate Research Center in Seattle inserted a gene into cells in the cerebellum, a small structure located at the back of the brain and tucked under the brain's larger cerebrum.

The cerebellum's primary function is controlling motor movements. Disorders of the cerebellum generally lead to often disabling loss of coordination. Recent research suggests the cerebellum may also be important in learning and may be involved in such conditions as autism and schizophrenia.

The cells the scientists selected to study are called Purkinje cells. These cells, named after their discoverer, Czech anatomist Jan Evangelista Purkinje, are some of the largest in the human brain. They typically make connections with hundreds of other brain cells.

"The Purkinje cell is a mysterious cell," said Horwitz. "It's one of the biggest and most elaborate neurons and it processes signals from hundreds of thousands of other brain cells. We know it plays a critical role in movement and coordination. We just don't know how."

The gene they inserted, called channelrhodopsin-2, encodes for a light-sensitive protein that inserts itself into the brain cell's membrane. When exposed to light, it allows ions - tiny charged particles - to pass through the membrane. This triggers the brain cell to fire.

The technique, called optogenetics, is commonly used to study brain function in mice. But in these studies, the gene must be introduced into the embryonic mouse cell.

"This 'transgenic' approach has proved invaluable in the study of the brain," Horwitz said. "But if we are someday going to use it to treat disease, we need to find a way to introduce the gene later in life, when most neurological disorders appear."

The challenge for his research team was how to introduce channelrhodopsin-2 into a specific cell type in an adult animal. To achieve this, they used a modified virus that carried the gene for channelrhodopsin-2 along with segment of DNA called a promoter. The promoter stimulates the cell to start expressing the gene and make the channelrhodopsin-2 membrane protein. To make sure the gene was expressed only by Purkinje cells, the researchers used a promoter that is strongly active in Purkinje cells, called L7/Pcp2."

In their paper, the researchers reported that by painlessly injecting the modified virus into a small area of the cerebellum of rhesus macaque monkeys, the channelrhodopsin-2 was taken up exclusively by the targeted Purkinje cells. The researchers then showed that when they exposed the treated cells to light through a fine optical fiber, they were able stimulate the cells to fire at different rates and affect the animals' motor control.

Horwitz said that it was the fact that Purkinje cells express L7/Pcp2 promoter at a higher rate than other cells that made them more likely to produce the channelrhodopsin-2 membrane protein.

"This experiment demonstrates that you can engineer a viral vector with this specific promoter sequence and target a specific cell type," he said. "The promoter is the magic. Next, we want to use other promoters to target other cell types involved in other types of behaviors."

Explore further: New insights into control of neuronal circuitry could lead to treatments for an inherited motor disorder

More information: Yasmine El-Shamayleh et al, Selective Optogenetic Control of Purkinje Cells in Monkey Cerebellum, Neuron (2017). DOI: 10.1016/j.neuron.2017.06.002

Journal reference: Neuron

Provided by: University of Washington

Viruses have evolved to be highly effective vehicles for delivering genes into cells. Seeking to take advantage of these traits, scientists can reprogram viruses to function as vectors, capable of carrying their genetic cargo ...

Carnegie Mellon University scientists can now use brain activation patterns to identify complex thoughts, such as, "The witness shouted during the trial."

Since scientists began studying the brain, they have asked whether the biology they observed can really be tied to external behaviors. Researchers are building a substantial understanding of the biophysical, molecular, and ...

UW Medicine researchers have developed a technique for inserting a gene into specific cell types in the adult brain in an animal model.

Humans are diurnal animals, meaning that we usually sleep at night and are awake during the day, due at least in part to light or the lack thereof. Light is known to affect sleep indirectly by entrainingmodifying the length ...

Different types of memories stored in the same neuron of the marine snail Aplysia can be selectively erased, according to a new study by researchers at Columbia University Medical Center (CUMC) and McGill University and published ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Study shines light on brain cells that coordinate movement - Medical Xpress

Cancer hijacks natural cell process to survive – Medical Xpress – Medical Xpress

June 26, 2017 Credit: CC0 Public Domain

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by the University of Oxford.

Non-sense mediated decay (NMD) is a natural physiological process that provides cells with the ability to detect DNA errors called nonsense mutations. It also enables these cells to eliminate the mutated message (decay) that comes from these faulty genes, before they can be translated into proteins that can cause disease formation. NMD is known among the medical community for the role it plays in the development of genetic diseases such as Cystic Fibrosis and some hereditary forms of cancers. But not all nonsense mutations can elicit NMD, so until now, it's wider impact on cancer was largely unknown.

Biomedical researchers and computer scientists from the University of Oxford Medical Sciences Division and the University of Birmingham developed a computer algorithm to mine DNA sequences from cancer to accurately predict whether or not an NMD would eliminate genes that had nonsense mutations. The work originally focused on ovarian cancers, and found that about a fifth of these cancers use NMD, to become stronger. This is because NMD ensures that the message from a gene called TP53, which ordinarily protects cells from developing cancer is almost completely eliminated. In the absence of NMD, a mutated TP53 might still retain some activity but NMD ensures that this is not the case.

Based on this research, the team predicts that because cancers essentially feed on NMD, they become dependent on it in some cases. If scientists were therefore able to inhibit or control the process, it is possible that they could also control cancer and prevent the progression of the disease.

Dr Ahmed Ahmed, Co-author and Professor of Gynaecology Oncology at the Nuffield Department of Obstetrics & Gynaecology and the head of the Ovarian Cancer Cell Laboratory, at the Weatherall Institute of Molecular Medicine at the University of Oxford, said: "Our first observations of evidence of the role of NMD in ovarian cancer were tantalizing. We found that NMD precisely explained why there was almost no expression of TP53 in certain ovarian cancers. We went on to test the role of NMD in other cancer types and the evidence of the role of NMD was compelling. This opens the door for exciting possibilities for customised treatments including individualized immunotherapies for patients in the future."

Following the ovarian cancer analysis, the team expanded the study to include other cancer types. They analysed about a million different cell mutations in more than 7,000 tumours from the Cancer Genome Atlas covering 24 types of cancer. The team was able to map how each cancer type used NMD revealing the remarkable extent to which NMD helps cancer to survive.

Katherine Taylor, CEO of Ovarian Cancer Action, who part-funded the research, said: "This is very exciting news. Professor Ahmed and his team have identified how cancer cells rely on a process called NMD for their survival. This discovery could help clinicians identify and inhibit the process, giving them much better control of a person's cancer.

"Ovarian cancer is a very complicated disease and survival rates are low, with only 46% of women living beyond five years after diagnosis. So understanding how we can prevent the disease from thriving is imperative if we are to improve the outcome for more women.

"It's fantastic to see how our funding is helping make real progress and we couldn't do this without the generosity of our supporters. We look forward to seeing where Professor Ahmed takes his research next."

Moving forward the team will focus on testing their theory and understanding to what degree stopping the NMD process allows them to control tumours.

Co-author, Dr Christopher Yau, a computational scientist at the Institute of Cancer and Genomic Sciences, University of Birmingham said: "As a result of these findings, we now plan to apply the same computer algorithm to determine if NMD affects cancer patients in The 100,000 Genomes Project. These investigations may pave the way to new treatment possibilities for NHS patients in the future."

Explore further: Two Oxford research discoveries offer hope for managing ovarian cancer

More information: The full paper citation is 'A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay,' and it will be published in Nature Communications on Monday 26 June 2017.

Oxford University researchers have found a way to detect ovarian cancer early and identified an enzyme that is key in making ovarian cancer more deadly. Their results, published in two journals, provide new research routes ...

Levels of circulating tumor DNA (ctDNA) detected in a blood test are correlated with the size of ovarian cancers and can predict a patient's response to treatment or time to disease progression, according to a retrospective ...

Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.

A recent discovery by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) may lead to a new treatment strategy for an aggressive ovarian cancer subtype.

A new discovery that sheds light on the genetic make up of ovarian cancer cells could explain why some women survive longer than others with this deadly disease. A multi-disciplinary team led by the Research Institute of ...

Mutations in the BRCA1 gene are one of the most common risk factors for breast and ovarian cancers. Although tumors that harbor BRCA1 mutations initially respond well to cancer treatments, many tumors eventually become less ...

Cancer tumours manipulate a natural cell process to promote their survival suggesting that controlling this mechanism could stop progress of the disease, according to new research led by the University of Oxford.

An international research team has found a way to improve the anti-cancer effect of a new medicine class called 'Smac mimetics'.

A subgroup of patients with osteosarcoma - a form of bone cancer - could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer ...

Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber ...

A team of researchers at McMaster University has identified a unique feature of cancer stem cells that can be exploited to kill the deadly cells thought to be the reason that cancer comes back after therapy. Understanding ...

Research from the Stowers Institute provides evidence suggesting that cancer cells might streamline their genomes in order to proliferate more easily. The study, conducted in both human and mouse cells, shows that cancer ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:
Cancer hijacks natural cell process to survive - Medical Xpress - Medical Xpress

Israeli Scientists Offer Simple Test to Identify Diseases from Dying Cells – The Jewish Press – JewishPress.com

Photo Credit: Hebrew University

One of the holy grails of medical research is the development of a simple non-invasive test that can detect a variety of diseases with high accuracy. To date there is no single diagnostic test that fulfills this function.

To solve this problem, Prof. Yuval Dor and Dr. Ruth Shemer at the Hebrew University of Jerusalem (together with Prof. Ben Glaser, Head of the Endocrinology Department at the Hadassah Medical Center) developed a new blood test that looks for the remnants of dying cells cast off by specific tissue types throughout the body.

When cells die, they release DNA fragments into the circulatory system. The DNA of each type of dying cell carries a unique chemical modification called methylation. By detecting the unique methylation signatures of DNA from the fragments of dying cells, Prof. Dor and Dr. Shemer have established a way to detect multiple disease processes including diabetes, cancer, traumatic injury and neurodegeneration in a highly sensitive and specific manner.

Prof. Dor and Dr. Shemer are researchers at the Institute for Medical Research-Israel Canada (IMRIC) in the Hebrew Universitys Faculty of Medicine. Both earned their PhDs at the Hebrew University.

A test that accurately pinpoints tissue damage from dying cells DNA fragments could hold the key to a variety of medical advances from a deeper understanding of human tissue dynamics, to earlier detection of life-threatening illnesses, to more efficient monitoring of responses to medical therapies.

Prof. Dor and Dr. Shemer envision a future where the continued research and refinement of their new technology will lead to a universal, rapid, sensitive and quantitative blood test for tissue-specific cell death. This blood test could be used to assess multiple pathologic conditions simultaneously, equivalent to standard blood chemistry panels in use today.

Their paper describing the method and its applications was published in the Proceedings of the National Academy of Sciences, in 2016, drawing considerable interest from the scientific and popular media. In recognition of their work, Prof. Dor and Dr. Shemer were awarded the Kaye Innovation Award for 2017.

Aurum Ventures MKI Ltd., the technology investment arm of Morris Kahn, provided Yissum, the Technology Transfer arm of the Hebrew University, with $1.2 million of funding for research and development of this new diagnostic approach. Earlier this year, OnTimeBio was founded to make Prof. Dors and Dr. Shemers vision become a reality.

See the original post here:
Israeli Scientists Offer Simple Test to Identify Diseases from Dying Cells - The Jewish Press - JewishPress.com

Best Hair Treatment | Ovation Hair Cell Protein Therapy

Recommended For You

Cell Therapy Hair Treatment

12oz

$56.95 New

worth 9 loyalty points

All Hair Types

The unique micro-technology of the complex proteins in Cell Therapy penetrate the hair cortex, building strand strength from within.

Use 2-3 times per week.

Prepare hair by washing with an Ovation Hair Shampoo.

Place a quarter to half dollar size amount (depending on hair length) of Ovation Cell Therapy in your palm. Massage into scalp and comb through to ends. Leave on for 3-5 minutes and rinse thoroughly.

Follow with an Ovation Conditioner or Crme Rinse.

Towel dry and style as desired.

I see my hairdresser every 5 weeks. She has commented on how fast my hair is growing and how healthy it looks. When she asked what I was doing differently, I told her Ovation Hair! She is very impressed.

Pamela W.

Your products have made my hair beautiful and given me confidence. Thank you!

Chip L.

I have seen a tremendous improvement in my hair's texture and overall look. It has its bounce back and I don't have broken split ends any longer!

Tammie F.

Love your products! Noticeable difference in hair thickness and health!

Mary D.

The Ovation Cell Therapy Hair & Scalp Treatment and Ovation Intensive Repair Hair Mask are lifesavers. I use them both about three times a week and they have really helped my hair. It has grown out stronger and the rest of it is healthier.

Katie L.

What ingredients in Cell Therapy Hair & Scalp Treatment make it effective?

Cell Therapy Hair Treatment nourishes the hair and scalp with proteins, vitamins, and amino acids that bind and absorb into the hair shaft to create thicker, longer, stronger, and visibly healthier hair.

How much Cell Therapy Hair Treatment should I apply with each treatment?

A quarter to half dollar size amount, depending on hair length.

How often should I use Cell Therapy Hair & Scalp Treatment?

We recommend incorporating Cell Therapy into your haircare washing regime 2-3 times per week. Do not exceed three Cell Therapy Hair Treatment applications between shampoos. Overuse of Cell Therapy Hair Treatment may result in stiff or weighed down hair, and possible breakage. Call us for a personalized regime to work Cell Therapy into your haircare routine at 888.411.3252 Option 2.

Can I use Cell Therapy Hair & Scalp Treatment with other hair growth or strengthening products?

Ovation products are not medicated; we do not recommend that you use in combination with medicated hair growth products. Please consult your stylist or dermatologist before incorporating any other product into our Ovation Hair Care Systems.

Should I use Cell Therapy Hair & Scalp Treatment if I have a Brazilian Blowout or Keratin Treatment?

We recommend consulting with your stylist before incorporating Cell Therapy into your hair care routine if you have a Brazilian Blowout or Keratin Treatment. Cell Therapy contains keratin and proteins which could cause protein overexposure, leading to dry, brittle hair. Please keep in mind our sulfate-free shampoos and conditioners are safe to use anytime.

See the original post:
Best Hair Treatment | Ovation Hair Cell Protein Therapy

Venturis Clinic Now Offering Complimentary Webinar on the Benefits of Amniotic Stem Cell Therapy – Benzinga

Venturis Clinic is now offering a complimentary webinar to anyone interested in learning more about amniotic stem cell therapy. Attendance is online and available from anywhere, with the webinar occurring on June 27th.

Oklahoma City, OK (PRWEB) June 26, 2017

Venturis Clinic is now offering a free webinar titled "The 411 on Avoiding Surgery with Amniotic Stem Cell Therapy." The webinar is scheduled for Tuesday, June 27th at 8:00 PM EST (5:00 PM PST). Anyone can participate virtually by signing up at https://r3stemcell.com/patient-webinar-signup with a special offer being available to all attendees.

The webinar will be hosted by R3 Stem Cell CEO David Greene, MD, MBA. Venturis Clinic is an R3 Center of Excellence, offering the amniotic stem cell procedures with Board Certified providers affiliated with the University of Oklahoma.

Venturis Clinic has performed an exceptional amount of the nonoperative regenerative medicine procedures, and helped many patients avoid the need for potentially risky surgery. Treatment with amniotic stem cell therapy is available in both Oklahoma City and Tulsa.

There is no charge for the webinar, and viewers will receive a significant special bonus offer at the end. The webinar is easily viewable on one's computer using the link sent after registering. During the live webinar, individuals will be able to ask questions.

Topics covered will include FAQ's, cell counts with amniotic therapy, insurance coverage, IRB research, outcomes with the treatment, comparisons to other methods and much more. People will be educated consumers after viewing the webinar, which will also be available on replay afterwards as well.

For those who would like to sign up for the FREE Webinar: The 411 on Amniotic Stem Cell Treatment simply visit the link above. To schedule appointments with Venturis Clinic for a free consultation, call (844) GET-STEM.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14458844.htm

More:
Venturis Clinic Now Offering Complimentary Webinar on the Benefits of Amniotic Stem Cell Therapy - Benzinga

Existing Drug Found to be Effective at Killing Cancer Stem Cells – Technology Networks

Researchers experiment with the Sam68 protein. Credit: McMaster University

A team of researchers at McMaster University has identified a unique feature of cancer stem cells that can be exploited to kill the deadly cells thought to be the reason that cancer comes back after therapy. Understanding this feature will be useful for delivering more targeted cancer therapeutics to the right patients.

The study, published today in the scientific journal Cell Chemical Biology, reveals that an existing set of drugs is effective in killing cancer stem cells and explains how this led the team to uncovering important details about how these cells are working in human tumors.

"The drugs helped us to understand the biology," said Mick Bhatia, principal investigator of the study and scientific director of the McMaster Stem Cell and Cancer Research Institute. "We've worked backwards, employing a series of drugs used in the clinic to understand a new way that cancer stem cells can be killed."

The researchers found that a particular protein, called Sam68, is an important actor in cancer stem cells, and that this protein allows existing drugs to work on cancer cells, causing them to die.

Bhatia hopes that this information can be used to deliver targeted therapies to the patients who would benefit from them, while sparing others from unhelpful treatments. He believes that treatment of blood cancers like leukemia and other cancers such as prostate, colon and renal will follow the example set in breast cancer, where patients receive treatments tailored to their specific form of the disease.

"In the case of breast cancer, other researchers have found new ways to make existing drugs more effective by only giving them to people who were likely to benefit based on their specific traits and using drugs that target these traits," Bhatia said.

He said while developing a new drug takes an average of about 15 years and comes with a price tag in the hundreds of millions, defining the role of existing drugs to use them better in patients will help to accelerate the process of bringing the right drugs to the right people.

Reference

Mickie Bhatia et al. Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology, June 2017 DOI: 10.1016/j.chembiol.2017.05.026

See the original post here:
Existing Drug Found to be Effective at Killing Cancer Stem Cells - Technology Networks

Large-scale production of living brain cells enables entirely new research – Medical Xpress

June 26, 2017

Important pieces of the puzzle to understand what drives diseases such as Alzheimer's and Parkinson's are still missing today. One crucial obstacle for researchers is that it is impossible to examine a living brain cell in someone who is affected by the disease. With the help of a new method for cell conversion, researchers at Lund University in Sweden have found a way to produce diseased, aging brain cells on a large scale in a cell culture dish.

After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient. The fact that the cells can now be produced in large quantities enables researchers to carry out a series of experiments that were previously not possible.

A few years ago, Malin Parmar's research team was one of the first in the world to convert human skin cells directly into brain cells without passing the stem cell state. The discovery shocked the researchers and was perceived as almost impossible. The team is now approaching a point where the discovery is about to bear fruit on a wide scale. By following a new method that involves slightly changing the genetic code that triggers cell conversion, the researchers were able to multiply the production of disease-specific brain cells.

"Primarily, we inhibited a protein, REST, involved in establishing identity in cells that are not nerve cells. After limiting this protein's impact in the cells during the conversion process, we've seen completely different results. Since then, we've been playing around with changing the dosage of the other components in the previous method, which also proved effective. Overall, the efficiency is remarkable. We can now generate almost unlimited amounts of neurons from one skin biopsy", says Malin Parmar, professor of developmental and regenerative neurobiology at Lund University.

The video will load shortly

The increase in production will have far-reaching effects. The new volumes enable research projects that were simply not viable before. Among other things, it opens up research areas linked to new drug testing, the establishment of more accurate disease models and the development of diagnostics to detect the diseases at an earlier stage.

The new cells are not only able to imitate the disease but also the patient's age. By studying the cell in the culture dish, the researchers can now monitor the mechanisms of the disease in an "old" brain cell over time. Neurodegenerative diseases are commonly referred to as "aging brain diseases" and in order to understand them, we must better appreciate how the age specifically affects the course of the disease. The Lund researchers' discovery can hopefully contribute a crucial piece to the puzzle with regard to the connection between the onset of disease and cell aging, something which previous research based on animal experiments and stem cells has failed to provide.

"This takes us one step closer to reality, as we can now look inside the human neurons and see what goes on inside the cell in these diseases. If all goes well, this could fundamentally change the field of research, as it helps us better understand the real mechanisms of the disease. We believe that many laboratories around the world would like to start testing on these cells to get closer to the diseases", says Johan Jakobsson, leader of the molecular neurogenetics research group at Lund University.

Explore further: Researchers form new nerve cellsdirectly in the brain

The field of cell therapy, which aims to form new cells in the body in order to cure disease, has taken another important step in the development towards new treatments. A new report from researchers at Lund University in ...

Using human skin cells, University of California, Irvine neurobiologists and their colleagues have created a method to generate one of the principle cell types of the brain called microglia, which play a key role in preserving ...

Wellcome Trust Sanger Institute scientists and their collaborators at the University of Cambridge have created a new technique that simplifies the production of human brain and muscle cells - allowing millions of functional ...

Researchers at Karolinska Institutet have made significant progress in the search for new treatments for Parkinson's disease. By manipulating the gene expression of non-neuronal cells in the brain, they were able to produce ...

The first transplantation of stem cells in patients with Parkinson's disease is almost within reach. However, it remains a challenge for researchers to control stem cells accurately in the lab in order to achieve successful ...

The sex of animals frequently has an effect in biomedical research and therefore should be considered in the study of science, report scientists from the Wellcome Trust Sanger Institute and the International Mouse Phenotyping ...

When women undergo lumpectomies to remove breast cancer, doctors try to remove all the cancerous tissue while conserving as much of the healthy breast tissue as possible.

Your brain is armored. It lives in a box made of bones with a security system of vessels. These vessels protect the brain and central nervous system from harmful chemicals circulating in the blood. Yet this protection systemknown ...

New research overturns long-held views on a basic messaging system within living cells. Key cellular communication machinery is more regionally constrained within the cell than previously thought. The findings suggest new ...

Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when transplanted into mice, according to research published June 22 in Cell Stem ...

The leading cause of acute gastroenteritis linked to eating raw seafood disarms a key host defense system in a novel way: It paralyzes a cell's skeleton, or cytoskeleton.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:
Large-scale production of living brain cells enables entirely new research - Medical Xpress

Scientist-backed PAC endorses Dana Rohrabacher’s challenger – Salon

Republican Rep. Dana Rohrabacher of California is a well-known science denier, particularly when it comes to the issue of man-made climate change. In response,314 Action, a new PAC that exists to help elect scientists to public office, is officially endorsing a Democratic rival to opposeRohrabacher in his 2018 reelection campaign.

Dr. Hans Keirstead is aPhD neuroscientist, cancer doctor and former UC Irvine School of Medicine professor, as well as the first non-incumbent endorsement that 314 Action has made.

Scientists are trained to follow the facts no matter where they lead, Keirstead toldSalon through email. Many times, a hypothesis does not get borne out by the facts. Science isnt about opinions or how you feel. Its about the pursuit of truth, and as a scientist, I have learned the value of real evidence and data. I believe my career developing successful, breakthrough cancer treatments through stem cell research will speak to people.

Keirsteads work on stem cell research has helped with treatment of various cancers, multiple sclerosis, and Lou Gehrigs disease, among other medical conditions.

Rohrabacher claims that he loves science,a fact that Keirstead insists is only the first step toward actually using science in a responsible way as a policymaker.

Understanding how science effects every day Americans lives? Thats where a policy maker who understands science makes their impact, Keirstead explained. I have seen firsthand how it can save lives by investing in medical research that leads to curing cancer or changing lives by providing jobs and infrastructure to a community like Orange County.

TheTrump administrations budget is a war on facts that the scientific community knows all about, saidShaughnessy Naughton, a chemist who founded 314 Action.

Whether its his massive cuts to research budgets, his views on climate change, vaccines, the decision to pull out of the Paris Agreement, or countless others, science is under attack right now. While we dont have a set criteria of policies for candidates who come to us, support for research funding and a recognition of the urgency with which we need to act on combating climate change.

Compare that with what is happening in Washington today with Trumps budget proposal,Keirstead added. They are slashing funding for the National Institute of Health and doubling user fees on small businesses. That has a direct effect on the work I and many in the medical field do. I guarantee you that if our research labs fees were doubled, my cancer treatment would not have gone to clinical trials. We need representatives who understand the direct consequences of their proposals and, sadly, Im not convinced many do.

It remains to be seen whether Naughton and Keirsteads support for reason can triumph not only in the laboratory, but in voting booths as well.

Go here to see the original:
Scientist-backed PAC endorses Dana Rohrabacher's challenger - Salon